NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Hoth Therapeutics Inc., a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, today announced the closing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share, resulting in aggregate gross proceeds of $7.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Hoth has granted the underwriters a 30-day option to purchase up to an additional 187,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments, if any.
Hoth’s common stock began trading on the Nasdaq Capital Market on February 15, 2019 under the ticker symbol “HOTH”.
Laidlaw & Company (UK) Ltd. acted as the sole book-running manager for the offering. The Benchmark Company, LLC served as Qualified Independent Underwriter for the offering.
About Hoth Therapeutics Incorporated
Hoth Therapeutics Inc., a Nevada corporation, is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform. Hoth intends to use the BioLexa Platform to develop two different topical cream products: (i) a product to treat eczema and (ii) a product that reduces post-procedure infections, accelerates healing and improves clinical outcomes for patients undergoing aesthetic dermatology procedures. Hoth’s initial focus will be on the development of the BioLexa Platform for the treatment of eczema. Eczema is a disease that results in inflammation of the skin and is characterized by rash, red skin, and itchiness. Eczema is also referred to as atopic dermatitis.

